Re: Riding the Xtandi coat tails

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Riding the Xtandi coat tails

in response to

Riding the Xtandi coat tails

masila

posted on Jul 16, 2018 10:52AM

Masila,

Thanks for sharing the news that enzalutamide is now approved for use in non-metastatic CRPC. Great news! I commented on the recently published PROSPER trial a couple of weeks ago in the linked posts below. My key point was:

"Therefore, if the non-metastatic, CRPC patient population is approved to start use of enzalutamide prior to the cancer becoming metastatic, then this increases the potential patient pool that will become enzalutamide resistant and potentially benefit from ZEN-3694."

Enzalutamide effective in non-metastatic prostate cancer

Re: Enzalutamide effective in non-metastatic prostate cancer

As for your comment on the increased adverse events/drug discontinuation in non-metastatic CRPC patients......the published PROSPER study acknowledges this observation but emphasized that "The safety profile of enzalutamide was consistent with that reported in previous clinical trials involving men with castration-resistant prostate cancer." In other words, no new surprises in non-metastatic CRPC patients than what was already known/observed in metastatic CRPC.